Advertisement

Cell Biochemistry and Biophysics

, Volume 72, Issue 2, pp 333–338 | Cite as

Breast Cancer: Epidemiology and Etiology

  • ZiQi TaoEmail author
  • Aimin Shi
  • Cuntao Lu
  • Tao Song
  • Zhengguo Zhang
  • Jing Zhao
Original Paper

Abstract

Breast cancer, the most frequently occurring cancer in women, is a major public health problem, with 1,384,155 estimated new cases worldwide with nearly 459,000 related deaths. Breast cancer is highly heterogeneous in its pathological characteristics, some cases showing slow growth with excellent prognosis, while others being aggressive tumors. Current predictions and statistics suggest that both worldwide incidence of breast cancer and related mortality are on the rise. According to 2012 GLOBOCAN statistics, nearly 1.7 million women were diagnosed with breast cancer with 522,000 related deaths—an increase in breast cancer incidence and related mortality by nearly 18 % from 2008. According to American Cancer Society, one in eight women in the United States will develop breast cancer in her lifetime. It has been predicted that the worldwide incidence of female breast cancer will reach approximately 3.2 million new cases per year by 2050. These numbers reflect the magnitude of breast cancer incidence, its effect on society worldwide and the need for urgency for preventive and treatment measures. While technological advances in medical sciences and health care have made it possible to detect the disease early and to start the treatment early on to prevent the progress of the disease into a metastatic state, there are several unanswered questions with regard to the molecular mechanisms that underlie the aggressiveness of certain forms of this disease. Epidemiological studies suggest that addressing socio economical issues is utmost important, so that all women have equal access to medical care from screening to advanced treatment, and only such decisive action can help reduce the worldwide burden of breast cancer.

Keywords

Breast cancer Epidemiology Etiology 

References

  1. 1.
    Verma, R., Bowen, R. L., Slater, S. E., Mihaimeed, F., & Jones, J. L. (2012). Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer. British Medical Bulletin, 103, 129–145.PubMedCrossRefGoogle Scholar
  2. 2.
    Druesne-Pecollo, N., Touvier, M., Barrandon, E., Chan, D. S., Norat, T., Zelek, L., et al. (2012). Excess body weight and second primary cancer risk after breast cancer: A systematic review and meta-analysis of prospective studies. Breast Cancer Research and Treatment, 135, 647–654.PubMedCrossRefGoogle Scholar
  3. 3.
    Youlden, D. R., Baade, P. D., Valery, P. C., Ward, L. J., Green, A. C., & Aitken, J. F. (2012). Childhood cancer mortality in australia. Cancer Epidemiology, 36, 476–480.PubMedCrossRefGoogle Scholar
  4. 4.
    Desantis, C., Ma, J., Bryan, L., & Jemal, A. (2014). Breast cancer statistics, 2013. CA A Cancer Journal for Clinicians, 64, 52–62.PubMedCrossRefGoogle Scholar
  5. 5.
    Hortobagyi, G. N., De La Garza Salazar, J., Pritchard, K., Amadori, D., Haidinger, R., Hudis, C. A., et al. (2005). The global breast cancer burden: Variations in epidemiology and survival. Clinical Breast Cancer, 6, 391–401.PubMedCrossRefGoogle Scholar
  6. 6.
    Anderson, W. F., Chatterjee, N., Ershler, W. B., & Brawley, O. W. (2002). Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Research and Treatment, 76, 27–36.PubMedCrossRefGoogle Scholar
  7. 7.
    Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747–752.PubMedCrossRefGoogle Scholar
  8. 8.
    Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 98, 10869–10874.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007). Descriptive analysis of estrogen receptor (er)-negative, progesterone receptor (pr)-negative, and her2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the california cancer registry. Cancer, 109, 1721–1728.PubMedCrossRefGoogle Scholar
  10. 10.
    Iwase, H., Kurebayashi, J., Tsuda, H., Ohta, T., Kurosumi, M., Miyamoto, K., et al. (2010). Clinicopathological analyses of triple negative breast cancer using surveillance data from the registration committee of the japanese breast cancer society. Breast Cancer, 17, 118–124.PubMedCrossRefGoogle Scholar
  11. 11.
    Park, S. Y., Lee, H. E., Li, H., Shipitsin, M., Gelman, R., & Polyak, K. (2010). Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clinical Cancer Research, 16, 876–887.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Hudis, C. A. (2007). Trastuzumab—mechanism of action and use in clinical practice. New England Journal of Medicine, 357, 39–51.PubMedCrossRefGoogle Scholar
  13. 13.
    Huang, H. J., Neven, P., Drijkoningen, M., Paridaens, R., Wildiers, H., van Limbergen, E., et al. (2005). Association between tumour characteristics and her-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. Journal of Clinical Pathology, 58, 611–616.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Cadoo, K. A., Fornier, M. N., & Morris, P. G. (2013). Biological subtypes of breast cancer: Current concepts and implications for recurrence patterns. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 57, 312–321.PubMedGoogle Scholar
  15. 15.
    Morris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P., et al. (2007). Differences in breast carcinoma characteristics in newly diagnosed african-american and caucasian patients: A single-institution compilation compared with the national cancer institute’s surveillance, epidemiology, and end results database. Cancer, 110, 876–884.PubMedCrossRefGoogle Scholar
  16. 16.
    Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., et al. (2007). Triple-negative breast cancer: Clinical features and patterns of recurrence. Clinical Cancer Research, 13, 4429–4434.PubMedCrossRefGoogle Scholar
  17. 17.
    Morris, P. G., Murphy, C. G., Mallam, D., Accordino, M., Patil, S., Howard, J., et al. (2012). Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast Journal, 18, 345–350.PubMedCrossRefGoogle Scholar
  18. 18.
    Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009). Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Research and Treatment, 115, 423–428.PubMedCrossRefGoogle Scholar
  19. 19.
    Phipps, A. I., Chlebowski, R. T., Prentice, R., McTiernan, A., Wactawski-Wende, J., Kuller, L. H., et al. (2011). Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. Journal of the National Cancer Institute, 103, 470–477.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Turpin, E., Bieche, I., Bertheau, P., Plassa, L. F., Lerebours, F., de Roquancourt, A., et al. (2002). Increased incidence of erbb2 overexpression and tp53 mutation in inflammatory breast cancer. Oncogene, 21, 7593–7597.PubMedCrossRefGoogle Scholar
  21. 21.
    Shirakawa, K., Kobayashi, H., Heike, Y., Kawamoto, S., Brechbiel, M. W., Kasumi, F., et al. (2002). Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Research, 62, 560–566.PubMedGoogle Scholar
  22. 22.
    Barrow, T. M., & Michels, K. B. (2014). Epigenetic epidemiology of cancer. Biochemical and Biophysical Research Communications, 455, 70–83.PubMedCrossRefGoogle Scholar
  23. 23.
    Huang, G. L., Zhang, X. H., Guo, G. L., Huang, K. T., Yang, K. Y., Shen, X., et al. (2009). Clinical significance of mir-21 expression in breast cancer: Sybr-green i-based real-time rt-pcr study of invasive ductal carcinoma. Oncology Reports, 21, 673–679.PubMedGoogle Scholar
  24. 24.
    Yan, L. X., Huang, X. F., Shao, Q., Huang, M. Y., Deng, L., Wu, Q. L., et al. (2008). Microrna mir-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348–2360.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Ambros, V. (2003). Microrna pathways in flies and worms: Growth, death, fat, stress, and timing. Cell, 113, 673–676.PubMedCrossRefGoogle Scholar
  26. 26.
    Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K., & Schwarzenbach, H. (2013). Deregulated serum concentrations of circulating cell-free micrornas mir-17, mir-34a, mir-155, and mir-373 in human breast cancer development and progression. Clinical Chemistry, 59, 1489–1496.PubMedCrossRefGoogle Scholar
  27. 27.
    Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J., Newell, J., & Kerin, M. J. (2010). Circulating micrornas as novel minimally invasive biomarkers for breast cancer. Annals of Surgery, 251, 499–505.PubMedCrossRefGoogle Scholar
  28. 28.
    Prabhu, J. S., Wahi, K., Korlimarla, A., Correa, M., Manjunath, S., Raman, N., et al. (2012). The epigenetic silencing of the estrogen receptor (er) by hypermethylation of the esr1 promoter is seen predominantly in triple-negative breast cancers in indian women. Tumour Biology, 33, 315–323.PubMedCrossRefGoogle Scholar
  29. 29.
    Wu, L., Wang, F., Xu, R., Zhang, S., Peng, X., Feng, Y., et al. (2013). Promoter methylation of brca1 in the prognosis of breast cancer: A meta-analysis. Breast Cancer Research and Treatment, 142, 619–627.PubMedCrossRefGoogle Scholar
  30. 30.
    Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D., Thompson, D., Ballinger, D. G., et al. (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087–1093.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Hughes, S., Agbaje, O., Bowen, R. L., Holliday, D. L., Shaw, J. A., Duffy, S., & Jones, J. L. (2007). Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clinical Cancer Research, 13, 6673–6680.PubMedCrossRefGoogle Scholar
  32. 32.
    Gutierrez-Fernandez, A., Fueyo, A., Folgueras, A. R., Garabaya, C., Pennington, C. J., Pilgrim, S., et al. (2008). Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Research, 68, 2755–2763.PubMedCrossRefGoogle Scholar
  33. 33.
    Decock, J., Long, J. R., Laxton, R. C., Shu, X. O., Hodgkinson, C., Hendrickx, W., et al. (2007). Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Research, 67, 10214–10221.PubMedCrossRefGoogle Scholar
  34. 34.
    Gajdos, C., Tartter, P. I., Bleiweiss, I. J., Bodian, C., & Brower, S. T. (2000). Stage 0 to stage iii breast cancer in young women. Journal of the American College of Surgeons, 190, 523–529.PubMedCrossRefGoogle Scholar
  35. 35.
    Toriola, A. T., & Colditz, G. A. (2013). Trends in breast cancer incidence and mortality in the united states: Implications for prevention. Breast Cancer Research and Treatment, 138, 665–673.PubMedCrossRefGoogle Scholar
  36. 36.
    Desantis, C., Siegel, R., Bandi, P., & Jemal, A. (2011). Breast cancer statistics, 2011. CA A Cancer Journal for Clinicians, 61, 409–418.PubMedCrossRefGoogle Scholar
  37. 37.
    Nelson, H. D., Zakher, B., Cantor, A., Fu, R., Griffin, J., O’Meara, E. S., et al. (2012). Risk factors for breast cancer for women aged 40 to 49 years: A systematic review and meta-analysis. Annals of Internal Medicine, 156, 635–648.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Colditz, G. A. (2007). Decline in breast cancer incidence due to removal of promoter: Combination estrogen plus progestin. Breast Cancer Research, 9, 108.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Smigal, C., Jemal, A., Ward, E., Cokkinides, V., Smith, R., Howe, H. L., & Thun, M. (2006). Trends in breast cancer by race and ethnicity: Update 2006. CA A Cancer Journal for Clinicians, 56, 168–183.PubMedCrossRefGoogle Scholar
  40. 40.
    Olopade, O. I., Fackenthal, J. D., Dunston, G., Tainsky, M. A., Collins, F., & Whitfield-Broome, C. (2003). Breast cancer genetics in african americans. Cancer, 97, 236–245.PubMedCrossRefGoogle Scholar
  41. 41.
    Kogevinas, M., Porta, M. (1997). Socioeconomic differences in cancer survival: A review of the evidence. IARC Scientific Publications, 138, 177–206.Google Scholar
  42. 42.
    McCormack, V. A., & Boffetta, P. (2011). Today’s lifestyles, tomorrow’s cancers: Trends in lifestyle risk factors for cancer in low- and middle-income countries. Annals of Oncology, 22, 2349–2357.PubMedCrossRefGoogle Scholar
  43. 43.
    Fan, L., Strasser-Weippl, K., Li, J. J., St Louis, J., Finkelstein, D. M., Yu, K. D., et al. (2014). Breast cancer in china. Lancet Oncology, 15, e279–e289.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • ZiQi Tao
    • 1
    Email author
  • Aimin Shi
    • 2
  • Cuntao Lu
    • 3
  • Tao Song
    • 4
  • Zhengguo Zhang
    • 5
  • Jing Zhao
    • 1
  1. 1.Department of Science and EducationXuzhou Central HospitalXuzhouChina
  2. 2.School of Public HealthNanjing Medical UniversityNanjingChina
  3. 3.Department of Breast SurgeryXuzhou Central HospitalXuzhouChina
  4. 4.Department of Gastrointestinal SurgeryXuzhou Central HospitalXuzhouChina
  5. 5.Department of Anorectal SurgeryXuzhou Central HospitalXuzhouChina

Personalised recommendations